Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
Medical professionals and liver disease specialists reported results from a study done on hep C infected organs and transplant recipients.
This includes people who use drugs, those with psychiatric disorders and those with a history of alcohol use.
A pooled analysis of numerous clinical trials and real-world studies reached this conclusion.
This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.
This rapid regimen could open the door for more transplantations of HCV-infected organs.
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
This hales another victory for improved treatment for hepatitis C.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
The presence of less studied HCV genotypes may compromise cure rates.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Researchers analyzed PPIs’ potential effects on nearly 2,400 participants of nine studies of Mavyret.
The U.S. FDA announced the approval of Mavyret, the first treatment for all hepatitis C genotypes in children ages 12 to 17.
The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.